Data / Drug companies / Saptalis Pharmaceuticals, LLC.
Saptalis Pharmaceuticals, LLC.: 21 products in the FDA NDC directory, labeler code 71656
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Saptalis Pharmaceuticals, LLC. (labeler code 71656) lists 21 products in the FDA National Drug Code Directory, covering 18 finished drugs by generic name. By type: 21 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 20, 2026.
The request: Watch Saptalis Pharmaceuticals, LLC. (FDA labeler code 71656): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 71656
- Products in commercial distribution
- 21
- Packages
- 39
- Finished drugs by generic name
- 18
- Prescription products
- 21
- Over the counter products
- 0
- Flagged as original packager
- 18 of 18 products that carry the flag
- Started marketing in the last 12 months
- 8
- Earliest marketing start
- September 27, 2023
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 19 | 90.5% |
| New drug applications (NDA) | 1 | 4.8% |
| Authorized generics (NDA) | 1 | 4.8% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 21 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Chlorpromazine hydrochloride | 2 | 27 |
| Triamcinolone acetonide | 2 | 77 |
| Desoximetasone | 2 | 14 |
| Metronidazole oral | 1 | 2 |
| Potassium chloride oral | 1 | 4 |
| Potassium chloride | 1 | 84 |
| Tofacitinib | 1 | 23 |
| Fluoxetine | 1 | 42 |
| Hydroxyzine hydrochloride | 1 | 51 |
| Cyclosporine | 1 | 24 |
| Lithium | 1 | 5 |
| Glycopyrrolate | 1 | 64 |
| Metformin hydrochloride | 1 | 79 |
| Metronidazole | 1 | 68 |
| Erythromycin topical solution 2% | 1 | 1 |
| Fluocinonide | 1 | 25 |
| Levocarnitine oral | 1 | 1 |
| Hydrocortisone and acetic acid otic | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Solution | 12 | 57.1% |
| Cream | 3 | 14.3% |
| Concentrate | 2 | 9.5% |
| Suspension | 1 | 4.8% |
| Emulsion | 1 | 4.8% |
| Lotion | 1 | 4.8% |
| Gel | 1 | 4.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Tofacitinib | 71656-071 | Solution | Generic drugs (ANDA) | August 20, 2026 |
| Hydroxyzine Hydrochloride | 71656-090 | Solution | Generic drugs (ANDA) | June 17, 2026 |
| Fluocinonide | 71656-094 | Solution | Generic drugs (ANDA) | May 11, 2026 |
| Desoximetasone | 71656-087 | Cream | Generic drugs (ANDA) | May 7, 2026 |
| Desoximetasone | 71656-086 | Cream | Generic drugs (ANDA) | April 13, 2026 |
| Chlorpromazine Hydrochloride | 71656-102 | Concentrate | Generic drugs (ANDA) | March 4, 2026 |
| Chlorpromazine Hydrochloride | 71656-101 | Concentrate | Generic drugs (ANDA) | March 4, 2026 |
| Cyclosporine | 71656-012 | Emulsion | Generic drugs (ANDA) | December 12, 2025 |
| Fluoxetine | 71656-089 | Solution | Generic drugs (ANDA) | June 20, 2025 |
| Metronidazole vaginal | 71656-067 | Gel | Generic drugs (ANDA) | March 3, 2025 |
| Glycopyrrolate | 71656-061 | Solution | Generic drugs (ANDA) | November 25, 2024 |
| Erythromycin topical solution 2% | 71656-030 | Solution | Generic drugs (ANDA) | August 14, 2024 |
| Metformin Hydrochloride Oral Solution | 71656-017 | Solution | Generic drugs (ANDA) | July 31, 2024 |
| Triamcinolone Acetonide | 71656-040 | Lotion | Generic drugs (ANDA) | July 30, 2024 |
| Lithium | 71656-072 | Solution | Generic drugs (ANDA) | March 28, 2024 |
| Hydrocortisone and acetic acid | 71656-064 | Solution | Authorized generics (NDA) | February 23, 2024 |
| Levocarnitine | 71656-016 | Solution | Generic drugs (ANDA) | February 21, 2024 |
| Likmez | 71656-066 | Suspension | New drug applications (NDA) | October 13, 2023 |
| Potassium chloride | 71656-022 | Solution | Generic drugs (ANDA) | October 5, 2023 |
| Potassium chloride | 71656-021 | Solution | Generic drugs (ANDA) | October 5, 2023 |
| Triamcinolone Acetonide | 71656-042 | Cream | Generic drugs (ANDA) | September 27, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.